-
Mashup Score: 3FDA Grants Accelerated Approval To Telisotuzumab Vedotin for Certain Patients With NSCLC - 2 day(s) ago
The accelerated approval of telisotuzumab vedotin (Emrelis, AbbVie Inc) is specifically for patients with high c-Met protein overexpression.
Source: www.lungcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 18
The phase 3 IMforte trial has met its primary endpoints of OS and PFS, demonstrating a “clinically meaningful benefit” of lurbinectedin plus atezolizumab as first-line maintenance.
Source: www.lungcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
📰 The phase 3 IMforte trial has met its primary endpoints of OS and PFS, according to an announcement ahead of the #ASCO25 presentation to be given by @LuisPaz_Ares. ➡️ Learn more: https://t.co/qaCYTLI8cL #SCLC #ASCO2025 #lcsm https://t.co/1UzpgpPTF9
-
-
Mashup Score: 0
Find key news and updates in thoracic oncology from the 2025 ASCO Annual Meeting, taking place May 30 to June 3, 2025, in Chicago, Illinois.
Source: www.lungcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
⏰ We're counting down until #ASCO25 kicks off in Chicago tomorrow⏰ 🫁 We'll be live on-site to bring you all the latest thoracic oncology news! 📰 Follow us and stay tuned for #ASCO news here: https://t.co/WPyhxt1JRA #lcsm #lungcancer #ASCO2025 #NSCLC #SCLC https://t.co/eptsAbSjS1
-
-
Mashup Score: 12ASCO 2025: Thoracic, Head and Neck Oncologists Reflect on Research, Mentorship, and Collaboration - 4 day(s) ago
Coral Olazagasti, MD, and Maria Velez, MD, MS, share highlights in thoracic oncology and beyond from the 2025 American Society of Clinical Oncology Annual Meeting.
Source: www.lungcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
🤩 Wow! What an amazing #ASCO25! 🫁 Don't miss this great interview with @COlazagasti and @MomaVelez11, who joined us to reflect on research, mentorship, and collaboration at the annual meeting! ➡️ Watch: https://t.co/wQuNrdwRvy #lcsm @ASCO https://t.co/X8ZRz9cE1C
-
-
Mashup Score: 0
Find key news and updates in thoracic oncology from the 2025 ASCO Annual Meeting, taking place May 30 to June 3, 2025, in Chicago, Illinois.
Source: www.lungcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
⏰ We're counting down until #ASCO25 kicks off in Chicago tomorrow⏰ 🫁 We'll be live on-site to bring you all the latest thoracic oncology news! 📰 Follow us and stay tuned for #ASCO news here: https://t.co/WPyhxt1JRA #lcsm #lungcancer #ASCO2025 #NSCLC #SCLC https://t.co/eptsAbSjS1
-
-
Mashup Score: 8Taletrectinib Gains FDA Approval for Locally Advanced or Metastatic ROS1-positive NSCLC - 6 day(s) ago
Overall response rate (ORR) and duration of response (DOR) were determined as “major efficacy outcome measures” through a blinded independent central review.
Source: www.lungcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
📰 BREAKING: The FDA has granted approval to taletrectinib for the treatment of locally advanced or metastatic ROS1-positive NSCLC. ➡️ Learn more: https://t.co/t83BLZLNOI #lcsm #NSCLC #ROS1 #lcsm https://t.co/vM3PrXJPx2
-
-
Mashup Score: 18
The phase 3 IMforte trial has met its primary endpoints of OS and PFS, demonstrating a “clinically meaningful benefit” of lurbinectedin plus atezolizumab as first-line maintenance.
Source: www.lungcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
📰 The phase 3 IMforte trial has met its primary endpoints of OS and PFS, according to an announcement ahead of the #ASCO25 presentation to be given by @LuisPaz_Ares. ➡️ Learn more: https://t.co/qaCYTLI8cL #SCLC #ASCO2025 #lcsm https://t.co/1UzpgpPTF9
-
-
Mashup Score: 10ASCO 2025: REZILIENT1 Insights From Dr. Helena Yu - 8 day(s) ago
The study evaluated zipalertinib in patients with NSCLC who have EGFR exon 20 insertion mutations and who have undergone platinum-based chemotherapy with or without amivantamab.
Source: www.lungcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
🫁 What's the latest on REZILIENT1? ⭐ Don't miss this insightful interview with Helena Yu, MD, of @MSKCancerCenter, who unpacks key data from her #ASCO25 oral abstract presentation on the study and discusses next steps. ➡️ Learn more: https://t.co/e4SAHCWmG1 #NSCLC #lcsm https://t.co/vnIJtMjOkd
-
-
Mashup Score: 0
Find key news and updates in thoracic oncology from the 2025 ASCO Annual Meeting, taking place May 30 to June 3, 2025, in Chicago, Illinois.
Source: www.lungcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
⏰ We're counting down until #ASCO25 kicks off in Chicago tomorrow⏰ 🫁 We'll be live on-site to bring you all the latest thoracic oncology news! 📰 Follow us and stay tuned for #ASCO news here: https://t.co/WPyhxt1JRA #lcsm #lungcancer #ASCO2025 #NSCLC #SCLC https://t.co/eptsAbSjS1
-
-
Mashup Score: 0KRYSTAL-7 Insights: Phase 2 Efficacy, Survival, Safety Results - 10 day(s) ago
Phase 2 investigated the clinical activity and safety profile of first-line adagrasib plus pembrolizumab for the treatment of advanced or metastatic KRASG12C-mutated NSCLC.
Source: www.lungcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
🫁 Adagrasib plus pembrolizumab showed “promising clinical efficacy” in the KRYSTAL-7 trial, according to an #ASCO25 presentation by Pasi Jänne, MD, PhD, FASCO, of @DFarberThoracic, @DanaFarber. ➡️ Learn more: https://t.co/miLOYioXWj #lcsm #NSCLC #KRAS #ASCO2025 https://t.co/dxcIQffIrz
-
🫁 Today, the @US_FDA granted accelerated approval to telisotuzumab vedotin for patients with locally advanced or metastatic NSCLC with high c-Met protein overexpression. ➡️ Learn more: https://t.co/DWu5NHBLuK #NSCLC #lcsm #FDA https://t.co/APGPnPbLSJ